Zenas BioPharma, Inc. Common Stock Asset Resilience Ratio
Zenas BioPharma, Inc. Common Stock asset resilience ratio. Zenas BioPharma, Inc. Common Stock (ZBIO) has an Asset Resilience Ratio of 63.64% as of June 2026. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. See ZBIO days of operational coverage to measure how many days the company can operate on defensive assets alone.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio of Zenas BioPharma, Inc. Common Stock (2023–2025)
Asset resilience ratio of Zenas BioPharma, Inc. Common Stock from 2023 to 2025. This chart shows how Zenas BioPharma, Inc. Common Stock's Asset Resilience Ratio has changed over time. Read how much debt does Zenas BioPharma, Inc. Common Stock carry for a breakdown of total debt and financial obligations.
Liquid Assets Composition Over Time
This chart breaks down Zenas BioPharma, Inc. Common Stock's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For the complete balance sheet picture, see ZBIO asset base.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 0% |
| Short-term Investments | $446.55 Million | 63.64% |
| Total Liquid Assets | $446.55 Million | 63.64% |
Asset Resilience Insights
- Very High Liquidity: Zenas BioPharma, Inc. Common Stock maintains exceptional liquid asset reserves at 63.64% of total assets.
- This level provides strong protection against economic uncertainties but may indicate potential for more aggressive growth investments.
- The company has significant short-term investments, indicating active treasury management.
Zenas BioPharma, Inc. Common Stock Industry Peers by Asset Resilience Ratio
Compare Zenas BioPharma, Inc. Common Stock's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
argenx NV ADR
NASDAQ:ARGX |
Biotechnology | 15.95% |
|
Halozyme Therapeutics Inc
NASDAQ:HALO |
Biotechnology | 12.71% |
|
Tubize-Fin
BR:TUB |
Biotechnology | 2.50% |
|
Ascendis Pharma AS
NASDAQ:ASND |
Biotechnology | 0.00% |
|
Madrigal Pharmaceuticals Inc
NASDAQ:MDGL |
Biotechnology | 62.31% |
|
3SBio Inc
F:83B |
Biotechnology | 10.64% |
|
Galapagos N.V.
AS:GLPG |
Biotechnology | 86.45% |
|
Chengzhi Shareholding Co Ltd
SHE:000990 |
Biotechnology | 6.12% |
Zenas BioPharma, Inc. Common Stock Asset Resilience Ratio by Year (2023–2025)
Zenas BioPharma, Inc. Common Stock asset resilience ratio by year from 2023 to 2025. The table below shows the annual Asset Resilience Ratio data for Zenas BioPharma, Inc. Common Stock.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2025-12-31 | 60.62% | $232.55 Million | $383.64 Million | +52.23pp |
| 2024-12-31 | 8.39% | $31.02 Million | $369.97 Million | -- |
| 2023-12-31 | 0.00% | $0.00 | $68.18 Million | -- |
About Zenas BioPharma, Inc. Common Stock
Zenas BioPharma, Inc., a clinical-stage biopharma company, engages in the development and commercialization of transformative immunology-based therapies. Its lead product candidate is obexelimab, a bifunctional monoclonal antibody designed to bind CD19 and Fc"RIIb for the treatment of various I&I diseases and various indications, including immunoglobulin G4-related disease, multiple sclerosis, an… Read more